Chiesi Farmaceutici and Aptuit have initiated a joint project aimed at identifying compounds for the potential treatment of idiopathic pulmonary fibrosis (IPF). Under terms of the agreement, both parties will contribute scientifically, with Aptuit providing discovery expertise, including medicinal chemistry and pharmacology, drug metabolism, and pharmacokinetics.

“We are very pleased to announce the partnership with Aptuit,” commented Dr. Mark Parry Billings, corporate drug development head, Chiesi Farmaceutici. “This alliance will allow our project to progress effectively to the identification of lead compounds with a novel mechanism of action, leveraging our joint expertise in respiratory drug discovery.”

The new agreement “builds on an existing relationship between Aptuit and Chiesi in the field of respiratory drug discovery,” noted Dr. Jonathan Goldman, Aptuit CEO. “We are delighted to be working with Chiesi to identify early stage compounds that we hope will ultimately progress into innovative treatments for patients with this debilitating disease.”

Aptuit offers fully integrated drug discovery to mid-phase drug development services from its sites in the U.K., Italy, and Switzerland. During 2016, the firm acquired U.K.-based CRO Kuecept, which specializes in drug preformulation, formulation prototyping, and formulation development services, and also acquired Swiss CRO Exquiron, which offers early-phase drug discovery solutions.